OSTX

OS Therapies Inc. (OSTX) - 10-K Filing Summary

Business Context and Reporting Period

Company: OS Therapies Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Overview: OS Therapies is a clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma (OS) and other solid tumors. The company operates as a single segment and conducts all operations remotely from Grasonville, Maryland. It has no commercial revenue and relies on financing to fund operations.

Key Pipeline Assets:

• OST-HER2: Lead product candidate, a cancer immunotherapy targeting HER2. Completed Phase IIb clinical trial in recurrent pulmonary metastatic Osteosarcoma. In October 2025, announced 75% two-year overall survival in treated patients vs. 40% in historical controls. Submitted Non-Clinical and CMC modules of Biologics License Application (BLA) to the FDA in January 2026.
• OST-tADC: Next-generation tunable antibody-drug conjugate platform currently in preclinical development.

Key Financial Metrics

Note: The filing text does not provide specific margin percentages as the company has no revenue.

Material Changes vs. Prior Period

• Expense Surge: Total operating expenses increased by approximately 321% from $6.8 million in 2024 to $28.7 million in 2025.
  • R&D Expenses: Rose from $2.8 million to $16.4 million, driven by costs associated with the Phase IIb clinical trial and regulatory submission preparations.
  • G&A Expenses: Rose from $4.0 million to $12.3 million, primarily due to marketing, investor relations, and legal fees related to financing activities.
• Liquidity Decline: Cash balances dropped from $5.5 million to $0.3 million due to high operational burn rates.
• Asset Acquisition: In April 2025, the company acquired HER2 Assets (including INDs for lung and prostate cancer) from Ayala Pharmaceuticals for $8.0 million (cash and stock), adding $6.5 million in intangible assets (patents).
• Financing Activity: Raised approximately $9.4 million in net cash from financing activities in 2025, primarily through warrant exercise inducement offerings and an ATM program.

Guidance, Outlook, Risks, and Contingencies

Outlook and Regulatory Pathway:

• Anticipates submitting the clinical BLA module to the FDA following a Type B meeting in Q2 2026.
• Plans to submit conditional Marketing Authorization Applications (MAA) to the MHRA (UK) and EMA (EU) in Q2 2026.
• Expects to initiate confirmatory clinical studies in Q3 2026.
• Eligible for a Priority Review Voucher if OST-HER2 receives FDA Accelerated Approval prior to September 30, 2029.

Going Concern Warning: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern for at least 12 months from the date of the report. The company has a net capital deficiency and recurring losses. Management plans to raise additional capital through equity or debt financing, but there is no assurance of success.

Key Risks:

• Capital Needs: Significant additional funding is required to support regulatory submissions, confirmatory trials, and commercialization. Failure to raise capital could force the company to delay or discontinue operations.
• Regulatory Uncertainty: No assurance that the FDA will approve OST-HER2 based on current data; a randomized Phase III trial may be required.
• Internal Controls: Management concluded that internal controls over financial reporting were not effective as of December 31, 2025, due to inadequate segregation of duties and insufficient written policies.
• Legal Contingency: An arbitration ruling in January 2026 awarded a former investment advisor approximately $1.38 million, which has been accrued as a liability.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $0.3 million cash balance against the stated need for approximately $25 million in vendor costs for regulatory efforts.
• Financing Status: Confirm the status of the March 2026 Bridge Financing ($2.0 million gross proceeds) and any subsequent capital raises to address the going concern warning.
• Regulatory Milestones: Monitor the outcome of the FDA Type B meeting expected in Q2 2026 and the subsequent BLA submission timeline.
• Internal Controls: Review management's remediation plan for the material weaknesses in internal controls over financial reporting.
• Legal Liability: Confirm the payment status of the $1.38 million arbitration award accrued in 2025.
• Dilution Risk: Assess the impact of outstanding warrants, convertible preferred stock, and the ATM program on existing shareholders.